Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$29.54M+157.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jun Xu
- Sector
- Consumer Defensive
- Industry
- Grocery Stores
- Employees
- 329
- Beta
- 4.15
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.68
Financials
Revenue
$29.54M+157.5%Net Income
$-5.21MEBITDA
$-2.60MFree Cash Flow
$3.59MEPS (diluted)
$-10.30Shares Outstanding (diluted)
729.3K+91.9%Operating Expenses
$10.36MCash & Debt
$1.52MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $124.22M | $1.17M | $3.35 |
| 2024 | $58.04M | $-3.34M | $-9.50 |
| 2023 | $55.40M | $1.25M | $3.38 |
| 2022 | $41.98M | $-562.7K | $-1.52 |
| 2021 | $41.20M | $904.1K | $2.44 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MSS's reported EPS growth of 8.2% a year over 4 years.
- EPS in 5 years
- $4.97
- Implied price
- $74.53
- Return from $1.55
- 116.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $37.05 — today's price is already 95.8% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 11 | 13 | 15 | 17 | 19 |
|---|---|---|---|---|---|
| -1.8% | 85.0% | 91.2% | 96.8% | 101.8% | 106.3% |
| 3.2% | 94.4% | 101.0% | 106.8% | 112.1% | 116.8% |
| 8.2% | 103.8% | 110.7% | 116.8% | 122.3% | 127.3% |
| 13.2% | 113.2% | 120.4% | 126.8% | 132.6% | 137.8% |
| 18.2% | 122.6% | 130.2% | 136.9% | 142.9% | 148.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+33.33%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·8d ago·Positive
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026 FDA alignment provides potential path to accelerated approval based on objective response rate and full approval based on progression-free survival SAN DIEGO, Sept. 28, 2026 …
View source ↗ - Newsprnewswire.com·35d ago·Negative
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy Paxalisib Monotherapy Significantly Reduced Tumor Burden in Pre-Clinical Model of MSS/pMMR Colorectal Cancer, With the Addition of Pembrolizumab Driving a Further Reduction Paxalisib Was Well Tolerated as Monotherapy and in Combination with Checkpoint Inhibition Kazia is Preparing to Advance Paxalisib Into a Phase 2 Clinical Study to E…
View source ↗ - Newsaccessnewswire.com·41d ago·Neutral
…inancing and, Management Believes, Enhances Financial and Strategic Flexibility MONTEREY PARK, CA / ACCESS Newswire / August 26, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a U.S.-based specialty grocery retailer and emerging platform for technology-enabled business initiatives, today announced that all outstanding obligations under its convertible notes have been paid, satisfied or otherwise discharged, as applicable. Following the completion, no convertible…
View source ↗ - Newsglobenewswire.com·49d ago·Negative
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free survival supporting full approval Pivotal expansion to follow initial clinical data from the ongoing randomized Part A SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Oncolytics…
View source ↗
Earnings
Wed, Dec 30(in 3 months)
Consensus estimate $0.20 per share
Typical surprise -2.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 30$0.64 vs $0.64beat
- Tue, Mar 17$-8.00 vs $1.00miss
- Mon, Dec 22$-12.00 vs $-11.50miss
- Mon, Sep 22$-4.00 vs $-4.00beat
Estimates and results for MSS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MSS officers and directors.
- Bought
- $58k
- Sold
- $285k
9 trades
5 trades
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Hrt Financial Lpbought
- Hrt Financial Lpsold
- Hrt Financial Lpbought
- Xu Johnbought
10 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MSS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.